OPPM
BPMC

Opus Point Partners Management’s Blueprint Medicines BPMC Stock Holding History

Opus Point Partners Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$498K Hold
6,780
– – 0.9% 27
2019
Q2 		$640K Hold
6,780
– – 0.95% 26
2019
Q1 		$543K Buy
+6,780
New +$501K 0.74% 29

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Opus Point Partners Management's BPMC Position: Q3 2019 in Review

Opus Point Partners Management held its Blueprint Medicines (BPMC) position steady in Q3 2019 at 6,780 shares worth $498K. The position accounts for 0.9% of the portfolio, ranked #27.

Opus Point Partners Management first reported a position in BPMC in Q1 2019 and has held it in 3 quarters since. The position peaked at $640K in Q2 2019. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

  • Opus Point Partners Management held 6,780 shares of Blueprint Medicines worth $498K as of Q3 2019.
  • Opus Point Partners Management left its Blueprint Medicines share count unchanged in Q3 2019.
  • Blueprint Medicines made up 0.9% of Opus Point Partners Management's portfolio in Q3 2019, its #27 holding.
  • Opus Point Partners Management first reported a position in Blueprint Medicines in Q1 2019 and has held it in 3 quarters since.
  • Opus Point Partners Management's Blueprint Medicines position peaked at $640K in Q2 2019.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.